152 related articles for article (PubMed ID: 37706223)
1. Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis.
Lang Y; Lin Y; Li D; Liu J; Liu X
Cancer Med; 2023 Sep; 12(18):18447-18459. PubMed ID: 37706223
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
Zheng Z; Lin J; Zhu H; Cai H
Front Public Health; 2022; 10():893387. PubMed ID: 35774581
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
7. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis.
Liu X; Lang Y; Chai Q; Lin Y; Liao Y; Zhu Y
Front Pharmacol; 2022; 13():872196. PubMed ID: 36071854
[No Abstract] [Full Text] [Related]
11. Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
Zhou K; Li Y; Liao W; Zhang M; Bai L; Li Q
Oral Oncol; 2020 Aug; 107():104754. PubMed ID: 32428689
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
